resten-mp
Nucleic acidexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2003 (NCT00244647)
Timeline
Indications
Mechanism of action
- Myc proto-oncogene proteinANTISENSE INHIBITOR
MYC antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- resten-mp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00248066 | Phase 2 | Sep 1, 2005 | Harvard University, Sarepta Therapeutics, University of Duisburg-Essen |
| NCT00244647 | Phase 1 | Aug 1, 2003 | Sarepta Therapeutics, University of Nebraska |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sarepta Therapeutics | For profit | 2 | 2 | 2 | 2003 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Duisburg-Essen | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Nebraska | Academic/Hospital | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1